Graham Dixon
Chief Tech/Sci/R&D Officer bij MITHRA PHARMACEUTICALS S.A.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Laura Ila von Schantz | M | 42 | 10 jaar | |
Anders Olof Adolf Ekblom | M | 70 | 7 jaar | |
Wolfgang Albrecht | M | - |
HepaRegeniX GmbH
HepaRegeniX GmbH Miscellaneous Commercial ServicesCommercial Services HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany. | 7 jaar |
Jeffrey Pott | M | - | 29 jaar | |
Marcus Wallenberg | M | 68 | 25 jaar | |
Valérie Leroy | F | - | 8 jaar | |
Peter Ellmark | M | 51 | 6 jaar | |
Veronica Wallin | F | 38 | 3 jaar | |
Christophe Maréchal | M | - | 7 jaar | |
Jean-Michel Foidart | M | 75 | 25 jaar | |
Denise Goode | F | 66 | 2 jaar | |
Marie Svensson | F | 60 | 4 jaar | |
Hans-Peter Albert Ostler | M | 53 | 3 jaar | |
Eva Ulrika Sjökvist Saers | M | 62 | 3 jaar | |
Christian Homsy | M | 65 | 1 jaar | |
Roel Q. J. Schaapveld | M | - |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | 16 jaar |
Inge Beernaert | M | - | 1 jaar | |
Fanny Rozenberg | F | - | - | |
Stijn Vlaminck | M | - | 3 jaar | |
Sumeet Ambarkhane | M | 56 | 2 jaar | |
Laurence Schyns | F | - | 3 jaar | |
Cedric Darcis | M | - | - | |
Iskra Reic | F | - | 23 jaar | |
Benjamin Brands | M | - | 15 jaar | |
André Ostachkov | M | - |
Apaxen SA
Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020. | 5 jaar |
Wilko de Vette | M | - |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | - |
Lotfi Yelles Chaouche | M | - |
Apaxen SA
Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020. | 5 jaar |
Bart Wuurman | M | - |
Apaxen SA
Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020. | 4 jaar |
Søren Bregenholt | M | 53 | 3 jaar | |
Jean-Manuel Fontaine | M | - | 11 jaar | |
Brian S. Bronk | M | - |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | - |
Samuel Gerssen | M | - |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | - |
Lucas de Breed | M | - |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | - |
Elias Papatheodorou | M | 55 |
HepaRegeniX GmbH
HepaRegeniX GmbH Miscellaneous Commercial ServicesCommercial Services HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany. | 2 jaar |
Staffan Encrantz | M | 73 | 2 jaar | |
Audrey Legentil-Duméry | F | - | 9 jaar | |
Jacques Galloy | M | 53 | 1 jaar | |
Johannes G. C. P. Schikan | M | 66 |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | 9 jaar |
Eugene Berezikov | M | - |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | 18 jaar |
Edwin Cuppen | M | - |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | 18 jaar |
Margareta Elisabeth Björk | M | 63 | 22 jaar | |
Ruud Dobber | M | - | 27 jaar | |
Anette Sundstedt | M | 57 | 3 jaar | |
Andrea van Elsas | M | 58 |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | 3 jaar |
Valérie Gordenne | F | 51 | 3 jaar | |
Eva Sjökvist Saers | M | 62 | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Julie Brown | F | 62 |
Zeneca Garden Care
Zeneca Garden Care Pharmaceuticals: OtherHealth Technology Part of AstraZeneca PLC, Zeneca Garden Care is a British company that develops and manufactures pharmaceutical products, agrochemicals, and specialty chemicals. The private company is based in Macclesfield, UK. Zeneca Garden Care was acquired by Zeneca Group Plc on January 01, 1995 for $84.16 million. | 21 jaar |
François Fornieri | M | - | 23 jaar | |
Patrick J. Langlois | M | 78 | 5 jaar | |
Patricia van Dijck | M | 59 | - | |
David Brennan | M | 70 | 13 jaar | |
Peter James Arthur Benson | M | 69 | 10 jaar | |
Ajit Shetty | M | 77 | - | |
Raj Bhikhu Parekh | M | 63 | 19 jaar | |
Olivier de Beaumont | M | - | 5 jaar | |
Peter Bonfield | M | 79 | 12 jaar | |
Gavin Hill | M | 56 | 8 jaar | |
Piet Wigerinck | M | 58 | 13 jaar | |
Lennart Erik Jonas Sjögren | M | 58 | 6 jaar | |
Jean Bizzari | M | 69 | - | |
Per Norlén | M | 54 | 11 jaar | |
Julie Silber | F | 56 | - | |
Jean-Pierre Kinet | M | 70 | 4 jaar | |
Erik van den Eynden | M | 56 | 2 jaar | |
Vicki Sato | M | 75 | 3 jaar | |
Malin Carlsson | M | 56 | 3 jaar | |
Michael Zinda | M | 53 | 16 jaar | |
Liesbeth Weynants | F | 53 | 2 jaar | |
An Cloet | F | 53 | 2 jaar | |
Håkan Söderberg | M | - | 5 jaar | |
Howard Mitchell Rowe | M | 55 | 12 jaar | |
Anna Ulrika Danielsson | F | 52 | 5 jaar | |
David Smith | M | 58 | 10 jaar | |
Kenth Ingemar Petersson | M | 68 | 20 jaar | |
Angus Russell | M | 68 |
Zeneca Garden Care
Zeneca Garden Care Pharmaceuticals: OtherHealth Technology Part of AstraZeneca PLC, Zeneca Garden Care is a British company that develops and manufactures pharmaceutical products, agrochemicals, and specialty chemicals. The private company is based in Macclesfield, UK. Zeneca Garden Care was acquired by Zeneca Group Plc on January 01, 1995 for $84.16 million. | 19 jaar |
Christian Moretti | M | 78 | 2 jaar | |
Karl Arne Krister Borrebaeck | M | 76 | 20 jaar | |
Marc. A. A. A. L Coucke | M | 59 | - | |
Cecilia Hofvander | F | - | 4 jaar | |
Werner Cautreels | M | 71 | - | |
Tova Landström | M | - | - | |
Harrold van Barlingen | M | 58 | 13 jaar | |
Rudi Pauwels | M | 65 | 11 jaar | |
Kirsten Drejer | M | 68 | 2 jaar | |
Ferdinand Verdonck | M | 81 | 8 jaar | |
Tom Morris | M | 61 | 18 jaar | |
Joseph Jimenez | M | 64 | 5 jaar | |
Donna Dea | F | - | 18 jaar | |
Sarah Holland | F | 61 | 5 jaar | |
Tao Deng | M | 68 | 6 jaar | |
Debra White | F | 62 | 13 jaar | |
Lilian Birgitta Wikström | M | 63 | 5 jaar | |
Dame Bridget Ogilvie | F | - | - | |
Moira Daniels | F | 62 | 12 jaar | |
Jan Lundberg | M | 70 | 11 jaar | |
Barry Greene | M | 60 | 2 jaar | |
Elaine Sullivan | M | 63 | 15 jaar | |
Roger Adsett | M | 55 | 11 jaar | |
Hongming Chen | M | 53 | 3 jaar | |
Nils Anders Haegerstrand | M | 63 | 1 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
België | 32 | 32.00% |
Verenigd Koninkrijk | 28 | 28.00% |
Zweden | 24 | 24.00% |
Nederland | 9 | 9.00% |
Frankrijk | 6 | 6.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Graham Dixon
- Persoonlijk netwerk